News

Video

Revolutionizing Prostate Cancer Care: 2023’s Transformative Breakthroughs

Author(s):

Rana R. McKay, MDTanya B. Dorff, MD

Expert oncologists highlight 2023’s transformative new targeted therapies and phase 3 data sets transforming the treatment paradigm in advanced prostate cancer.

Related Videos
Anthony V. D'Amico, MD, PhD
Video 6 - "Reflex Testing for Patients with Suspected Lung Cancer"
Video 5 "Biomarker Testing in Early-Stage NSCLC"
Stephen J. Freedland, MD
Timothy Yap, MBBS, PhD, FRCP
Timothy Yap, MBBS, PhD, FRCP
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Kara N. Maxwell, MD, PhD
Zofia Piotrowska, MD, MHS, and Martin Dietrich, MD, PhD, experts on lung cancer
Related Content
Fernando Cotait Maluf, MD
June 7th 2024

Pembrolizumab With Platinum-Based Therapy is Safe and Efficacious in PSCC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

Stephen J. Freedland, MD
June 5th 2024

Enzalutamide Treatment Suspension Has No Significant Impact on QOL in nmHSPC

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

James A. Knight II, MD
May 28th 2024

Broadening Differentials in Brain-Metastatic Prostate Cancer Broadens Diagnostic Horizons

FDA
May 28th 2024

FDA Approval Sought for Use of TLX007-CDx in PSMA PET Imaging of Prostate Cancer